The present invention provides assay devices and methods for detecting the presence of an analyte in a sample. Devices according to the invention include a reagent zone, one or more capture zones and a detection zone. Capture zones can reduce the quantity of labelled conjugate that reaches the detection zone in the presence of a negative marker in the sample and/or in the absence of a positive marker in the sample, facilitating high sensitivity and improved specificity testing.

According to a first aspect of the invention, there is provided a device for estimation of an ovulation date, comprising a camera, configured to obtain colour data of successive FSH test strips and a processor, configured to evaluate the colour data obtained by the camera. The processor is configured to determine a concentration value of each successive FSH test strip based on the data of the camera and to output a signal, if the processor determines that a first FSH downward trend of the FSH test strip values is occurring in the successive FSH test strips.

The present invention provides a device for indicating a test result of a specimen using recognizable symbols, including a reagent strip, wherein the reagent strip includes a detection zone including an analyte binding area and a positive control area, and the positive control area includes a first-layer reagent and a second-layer reagent; the first-layer reagent is a reagent that becomes transparent when exposed to water, the second-layer reagent is a colored reagent, and the first-layer reagent is not transparent when dry but becomes transparent when wetted; or a device for indicating a test result of a specimen using recognizable symbols, which includes a reagent strip, and the reagent strip includes a detection zone including an analyte binding area and a positive control area; wherein the positive control area includes a light-emitting element which emits light after energizing, and the light emitted by the element is projected to the positive control area, thereby binding to the analyte binding area to form a symbol to indicate the test result.

The present invention provides polymersomes comprising amphiphilic block-copolymers and their use to quantify ammonia in samples (e.g., body fluid samples). More particularly, it provides a polymersome comprising (a) a membrane, which comprises a block copolymer of poly(styrene) (PS) and poly(ethylene oxide) (PEO), wherein the PS/PEO molecular weight ratio is higher than 1.0 and lower than 4.0; and (b) a core which encloses an acid and at least one pH-sensitive dye. Compositions, strips and kits comprising the polymersomes are also provided along with methods of quantifying ammonia in a sample using the polymersomes, compositions and kit.

Machine image detection involving a trained classifier is used to detect a result of a test stick diagnostic device configured to detect the presence of an analyte in a test sample. Example implementations include receiving a digital image comprising a depiction of at least a portion of a test stick diagnostic device and applying the digital image to a classifier configured to determine a relative position, relative orientation, and relative scale of the portion of the test stick diagnostic device with respect to the digital image, identify a test result region of the test stick diagnostic device, and detect a test result marking in the test result region of the test stick diagnostic device. An indication of a result of a diagnostic test may be provided based on the detected test result marking.

The disclosure provides for a newborn metabolic vulnerability profile that can be used to evaluate risk for neonatal mortality and major morbidity in preterm infants, methods of using said model for precision clinical monitoring and targeted investigation of etiologic pathways to reduce the incidence and severity of major morbidities associated with preterm birth.

A method for providing variable function medical tests, comprising providing by a mobile device application a plurality of selectable medical test functions, receiving information from the mobile device application regarding test results from a test performed using a testing device, wherein the testing device includes an alignment target disposed on the testing device and a plurality of immunoassay test strips receiving at the server an image of the testing device from the mobile device application, determining by the server RGB values for a plurality of pixels of the image, normalizing by the server the RGB values into a single value, comparing by the server the single value to a control value stored on the server, and providing by the server a risk indicator, wherein the risk indicator indicates a likelihood of a presence of a medical condition.

Systems and methods for detecting an analyte include test wands configured to employ immunochromatographic assay with new fluorescent labeling technology, a reading device that can specifically identify signals from wands and sync information to the mobile devices. The systems may quantitatively detect progesterone metabolites in urine to track the level changes, confirm ovulation, and/or evaluate menstruation status. The systems and methods assess and track an individual's ovulation cycle by monitoring a hormone pattern of that specific individual, and establishing a dynamic threshold as a baseline for changes in the specific subject's hormones.

Device for simultaneous and rapid determination of the fertility hormones estradiol, progesterone, luteinizing hormone and prolactin in saliva comprising a biosensor (10) provided with four working electrodes (12, 13, 14, 15), an auxiliary electrode (11) and a reference electrode (16) and a single potentiostatic circuit (2) having a single channel, which shares the auxiliary and reference electrodes, a multiplexer (3) to multiplex the signals from the four working electrodes, a transimpedance amplifier (4), an analog-digital signal converter (5) and a controller (6).

A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.